On the stock market since 2017, it operates in the world of health and science. It has 46 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 16% a year on average.
Sales run at $12.5M a year. A small number, but proof the product has real buyers.
It pays out $0.0002 per share each year — regular cash for whoever holds the stock.
A loss of $4.4M against $12.5M in annual sales.
The stock sits at $0.08. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, IMPZY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: IMPZY is a high-risk stock — not yet profitable, and its future rides on its product catching on.